

Development of Robust and Innovative Vaccine Effectiveness (DRIVE)

First published: 22/05/2019

Last updated: 20/08/2024

Network

Network identification

PURI

<https://redirect.ema.europa.eu/resource/35229>

Network ID

35229

Network countries

- Belgium
 - European Union
 - Finland
 - France
 - Italy
 - Netherlands
 - Spain
 - United Kingdom
-

Network website

<https://www.drive-eu.org>

ENCePP partner

No

Network description

DRIVE (Development of Robust and Innovative Vaccines Effectiveness) is a public private partnership that aims to advance European cooperation in influenza vaccine effectiveness studies. Its partners include public health institutions, universities, small and medium-sized enterprises, vaccine manufacturers, and patient organizations. DRIVE was formed in July 2017 and aims to establish a sufficiently sized network to generate robust, high quality, brand-specific effectiveness estimates for all influenza vaccines used in the EU each season. The data generated through DRIVE is expected to increase the understanding of influenza vaccine effectiveness, lead to enhanced monitoring of influenza vaccine performance by public health institutes and allow manufacturers to fulfil the requirements of the European Medicines Agency (EMA). DRIVE also aims to develop a sustainable and transparent governance model for public private partnerships.

Network details

Network primary therapeutic area:

- Immunological products and vaccines
- Infectious diseases

Network funding:

- • EU institutional research programme

- • Pharmaceutical company and other private sector

Contact

Mónica Vázquez-Moreno

Main

vazquez_monmor@gva.es

Díez-Domingo Javier

Alternate

jdiezdomingo@gmail.com